SCHEMBL7959965

SCHEMBL7959965

O=C(CCCl)c1cn(S(=O)(=O)c2ccccc2)c2c1CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
PLK1 P53350 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.36
FABP4 P15090 5/20 0.36
FABP3 P05413 1/20 0.36
PARL Q9H300 1/20 0.35
KDM4E B2RXH2 2/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C1 Q04828 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TNF P01375 1/20 0.35
HSD17B10 Q99714 2/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
HTR6 P50406 3/20 0.34
GLA P06280 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12748792 0.73 AKR1C3 (0.55) KMT2AMEN1AKR1C3AKR1C1ALDH1A1
SCHEMBL5790264 0.70 HTR6 (0.49) KMT2AMEN1PLK1LMNASMN1; SMN2
SCHEMBL8568212 0.69 CTDSP1 (0.40) LMNAALDH1A1HTR6MAPT
SCHEMBL22289952 0.64 FABP4 (0.37) KMT2AFABP4FABP3KDM4EALDH1A1
SCHEMBL7961094 0.62 HTR6 (0.47) KMT2AMEN1LMNAPARLALDH1A1
SCHEMBL19725538 0.61 MAPT (0.59) KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL22289935 0.61 FABP4 (0.35) KMT2APTGDR2FABP4FABP3KDM4E
SCHEMBL7799771 0.59 LMNA (0.68) KMT2AMEN1PLK1LMNASMN1; SMN2
SCHEMBL9788974 0.59 KLKB1 (0.47) KMT2AMEN1PLK1LMNASMN1; SMN2
SCHEMBL27622290 0.59 LMNA (0.72) KMT2AMEN1PLK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6187774-B1 N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-02-13 US disclosed
EP-0885883-A1 FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-12-23 EP disclosed